{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:06:33Z","timestamp":1789628793555,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"DOI":"10.1007\/s12185-026-04289-w","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:45:29Z","timestamp":1789627529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current perspectives on non-factor therapies for hemophilia"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-2782","authenticated-orcid":false,"given":"Yuto","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"9","key":"4289_CR1","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1111\/jth.15444","volume":"19","author":"R Gualtierotti","year":"2021","unstructured":"Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: current knowledge and future perspectives. J Thromb Haemost. 2021;19(9):2112\u201321.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"4289_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1055\/s-0037-1615621","volume":"85","author":"GC White 2nd","year":"2001","unstructured":"White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.","journal-title":"Thromb Haemost"},{"issue":"Suppl 6","key":"4289_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"5","key":"4289_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/rth2.12335","volume":"4","author":"LL Jardim","year":"2020","unstructured":"Jardim LL, Chaves DG, Rezende SM. Development of inhibitors in hemophilia A: an illustrated review. Res Pract Thromb Haemost. 2020;4(5):752\u201360.","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"4289_CR5","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1160\/TH16-01-0049","volume":"116","author":"CE Walsh","year":"2016","unstructured":"Walsh CE, Jim\u00e9nez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in hemophilia patients. Thromb Haemost. 2016;116(Suppl 1):S10\u20137.","journal-title":"Thromb Haemost"},{"issue":"1","key":"4289_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-2516.2006.01403.x","volume":"13","author":"J Astermark","year":"2007","unstructured":"Astermark J, Rocino A, Von Depka M, Van Den Berg HM, Gringeri A, Mantovani LG, et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with hemophilia and inhibitors. Haemophilia. 2007;13(1):38\u201345.","journal-title":"Haemophilia"},{"issue":"1","key":"4289_CR7","doi-asserted-by":"publisher","first-page":"100020","DOI":"10.1016\/j.rpth.2022.100020","volume":"7","author":"I Oomen","year":"2022","unstructured":"Oomen I, Camelo RM, Rezende SM, Voorberg J, Mancuso ME, Oldenburg J, et al. Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis. Res Pract Thromb Haemost. 2022;7(1):100020.","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"4289_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.clinthera.2012.01.001","volume":"34","author":"ZY Zhou","year":"2012","unstructured":"Zhou ZY, Hay JW. Efficacy of by-passing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther. 2012;34(2):434\u201345.","journal-title":"Clin Ther"},{"issue":"5","key":"4289_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s12185-014-1572-4","volume":"99","author":"K Ogiwara","year":"2014","unstructured":"Ogiwara K, Nogami K, Matsumoto T, Shima M. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor. Int J Hematol. 2014;99(5):577\u201387.","journal-title":"Int J Hematol"},{"issue":"5","key":"4289_CR10","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1182\/bloodadvances.2023011974","volume":"8","author":"CL Kempton","year":"2024","unstructured":"Kempton CL, Fedewa SA. Defining the impact of immune tolerance induction on clinically relevant outcomes in a US cohort of severe hemophilia A. Blood Adv. 2024;8(5):1190\u20139.","journal-title":"Blood Adv"},{"issue":"1","key":"4289_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/s-0044-1796651","volume":"51","author":"V Jim\u00e9nez-Yuste","year":"2025","unstructured":"Jim\u00e9nez-Yuste V. Non-factor therapies for hemophilia: achievements and perspectives. Semin Thromb Hemost. 2025;51(1):23\u20137.","journal-title":"Semin Thromb Hemost"},{"issue":"21","key":"4289_CR12","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044\u201353.","journal-title":"N Engl J Med"},{"issue":"9","key":"4289_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809\u201318.","journal-title":"N Engl J Med"},{"issue":"6","key":"4289_CR14","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/jth.15697","volume":"20","author":"AE Mast","year":"2022","unstructured":"Mast AE, Ruf W. Regulation of coagulation by tissue factor pathway inhibitor: implications for hemophilia therapy. J Thromb Haemost. 2022;20(6):1290\u2013300.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"4289_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S1357-2725(03)00244-9","volume":"36","author":"NS Quinsey","year":"2004","unstructured":"Quinsey NS, Greedy AL, Bottomley SP, Whisstock JC, Pike RN. Antithrombin: in control of coagulation. Int J Biochem Cell Biol. 2004;36(3):386\u20139.","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"4289_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1365-2141.2007.06693.x","volume":"138","author":"S Shetty","year":"2007","unstructured":"Shetty S, Vora S, Kulkarni B, Mota L, Vijapurkar M, Quadros L, et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of hemophilia patients. Br J Haematol. 2007;138(4):541\u20134.","journal-title":"Br J Haematol"},{"issue":"5","key":"4289_CR17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm.3847","volume":"21","author":"A Sehgal","year":"2015","unstructured":"Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21(5):492\u20137.","journal-title":"Nat Med"},{"issue":"9","key":"4289_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"4289_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","volume":"115","author":"Y Nakajima","year":"2022","unstructured":"Nakajima Y, Mizumachi K, Shimonishi N, Furukawa S, Yada K, Ogiwara K, et al. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients. Int J Hematol. 2022;115(4):489\u201398.","journal-title":"Int J Hematol"},{"issue":"14","key":"4289_CR20","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood.2020010331","volume":"138","author":"H \u00d8stergaard","year":"2021","unstructured":"\u00d8stergaard H, Lund J, Greisen PJ, Kjellev S, Henriksen A, Lorenzen N, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258\u201368.","journal-title":"Blood"},{"issue":"17","key":"4289_CR21","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2517384","volume":"394","author":"ME Mancuso","year":"2026","unstructured":"Mancuso ME, Chan AKC, Shanmukhaiah C, Lyu CJ, Zdziarska J, Mahlangu J, et al. Mim8 bispecific antibody prophylaxis in hemophilia A with or without inhibitors. N Engl J Med. 2026;394(17):1696\u2013709.","journal-title":"N Engl J Med"},{"issue":"2","key":"4289_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","volume":"22","author":"Y Teranishi-Ikawa","year":"2024","unstructured":"Teranishi-Ikawa Y, Soeda T, Koga H, Yamaguchi K, Kato K, Esaki K, et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophilic state. J Thromb Haemost. 2024;22(2):430\u201340.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"4289_CR23","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/j.jtha.2025.03.034","volume":"23","author":"K Ogiwara","year":"2025","unstructured":"Ogiwara K, Furukawa S, Inaba K, Sasai K, Nakajima Y, Shimonishi N, et al. Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A. J Thromb Haemost. 2025;23(7):2164\u201377.","journal-title":"J Thromb Haemost"},{"issue":"19","key":"4289_CR24","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood.2025031894","volume":"147","author":"K Nogami","year":"2026","unstructured":"Nogami K, You CW, Park YS, Chen YC, Shen MC, Wang JD, et al. NXTAGE: a phase 1\/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors. Blood. 2026;147(19):2261\u201371.","journal-title":"Blood"},{"issue":"9","key":"4289_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2216455","volume":"389","author":"T Matsushita","year":"2023","unstructured":"Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389(9):783\u201394.","journal-title":"N Engl J Med"},{"issue":"12","key":"4289_CR26","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1016\/S2352-3026(24)00307-7","volume":"11","author":"P Chowdary","year":"2024","unstructured":"Chowdary P, Angchaisuksiri P, Apte S, Astermark J, Benson G, Chan AKC, et al. Concizumab prophylaxis in people with hemophilia A or hemophilia B without inhibitors (explorer8): a prospective, multicenter, open-label, randomized, phase 3a trial. Lancet Haematol. 2024;11(12):e891-904.","journal-title":"Lancet Haematol"},{"issue":"2","key":"4289_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.18495","volume":"200","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Luis Lamas J, Cristobal Morales J, Malan DR, Teeter J, Charnigo RJ, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia: phase II study results. Br J Haematol. 2023;200(2):240\u20138.","journal-title":"Br J Haematol"},{"issue":"14","key":"4289_CR28","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood.2024027468","volume":"146","author":"D Matino","year":"2025","unstructured":"Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, et al. Marstacimab prophylaxis in hemophilia A\/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025;146(14):1654\u201363.","journal-title":"Blood"},{"issue":"9","key":"4289_CR29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1616569","volume":"377","author":"KJ Pasi","year":"2017","unstructured":"Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377(9):819\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"4289_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/jth.15270","volume":"19","author":"KJ Pasi","year":"2021","unstructured":"Pasi KJ, Lissitchkov T, Mamonov V, Mant T, Timofeeva M, Bagot C, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran\u2013results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436\u201346.","journal-title":"J Thromb Haemost"},{"issue":"10386","key":"4289_CR31","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","volume":"401","author":"G Young","year":"2023","unstructured":"Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You CW, et al. Efficacy and safety of fitusiran prophylaxis in people with hemophilia A or hemophilia B with inhibitors (ATLAS-INH): a multicenter, open-label, randomized phase 3 trial. Lancet. 2023;401(10386):1427\u201337.","journal-title":"Lancet"},{"issue":"5","key":"4289_CR32","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","volume":"10","author":"A Srivastava","year":"2023","unstructured":"Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, et al. Fitusiran prophylaxis in people with severe hemophilia A or hemophilia B without inhibitors (ATLAS-A\/B): a multicenter, open label, randomized, phase 3 trial. Lancet Haematol. 2023;10(5):e322\u201332.","journal-title":"Lancet Haematol"},{"issue":"22","key":"4289_CR33","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1182\/blood.2023021864","volume":"143","author":"G Kenet","year":"2024","unstructured":"Kenet G, Nolan B, Zulfikar B, Antmen B, Kampmann P, Matsushita T, et al. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial. Blood. 2024;143(22):2256\u201369.","journal-title":"Blood"},{"issue":"10","key":"4289_CR34","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1182\/bloodadvances.2024015201","volume":"9","author":"JA Huntington","year":"2025","unstructured":"Huntington JA, Reckless J, Polderdijk SGI, Hextall P, Baglin TP. The preclinical profile of SerpinPC: a potential new treatment for hemophilia. Blood Adv. 2025;9(10):2402\u20139.","journal-title":"Blood Adv"},{"key":"4289_CR35","unstructured":"World Federation of Hemophilia. WFH statement on recent developments related to hemophilia therapies. 2025. https:\/\/wfh.org\/article\/wfh-statement-on-recent-developments-related-to-hemophilia-therapies\/. Accessed 3 Mar 2026."},{"issue":"Suppl 1","key":"4289_CR36","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2022-170245","volume":"140","author":"L Leong","year":"2022","unstructured":"Leong L, Byun T, Kim B, Huck I. Pre-clinical characterization of VGA039, an anti-protein S monoclonal antibody being developed as a universal hemostatic agent for various bleeding disorders. Blood. 2022;140(Suppl 1):1666\u20137.","journal-title":"Blood"},{"key":"4289_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-9560-13-1","volume":"13","author":"MD Lanc\u00e9","year":"2015","unstructured":"Lanc\u00e9 MD. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J. 2015;13:1.","journal-title":"Thromb J"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04289-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04289-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04289-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:45:32Z","timestamp":1789627532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04289-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":37,"alternative-id":["4289"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04289-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"6 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yuto Nakajima received grants from Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and KM Biologics Co., Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}